Clinical Trials Logo

Hematologic Diseases clinical trials

View clinical trials related to Hematologic Diseases.

Filter by:

NCT ID: NCT05983536 Not yet recruiting - Cancer Clinical Trials

The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)

Start date: September 20, 2023
Phase:
Study type: Observational

To evaluate the anti-interference and specificity of HIV Ag +Ab Assay Kit (Sysmex) for the detection of HIV antigens and antibodies.

NCT ID: NCT05969821 Not yet recruiting - Lymphoma Clinical Trials

Clonal Hematopoiesis of Immunological Significance

CHIS
Start date: September 2023
Phase:
Study type: Observational [Patient Registry]

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

NCT ID: NCT05952817 Not yet recruiting - Blood Disease Clinical Trials

Physiotherapy for Children With Sickle Cell Disease: A Randomized Controlled Trial

RCT
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Primary aim to determine the effects of immersive VR on pain management in children with SCD. Secondary aim to determine the effects of immersive VR in musculoskeletal dysfunction in children with SCD and health-related quality of life.

NCT ID: NCT05581875 Not yet recruiting - Multiple Myeloma Clinical Trials

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Start date: October 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, open label, single-center study designed to assess the safety and preliminary clinical activity of different belantamab mafodotin doses in combination with daratumumab, pomalidomide, and dexamethasone (DPd) in patients with Relapsed/ Refractory Multiple Myeloma (RRMM) previously treated with one line of therapy who are lenalidomide refractory. This will be a 2-Part study. Part 1 will evaluate the safety of belantamab mafodotin in combination with DPd in 2 cohorts and determine the Recommended Phase 2 Dose (RP2D). In the dose expansion phase (Part 2) an expansion cohort will be treated with the RP2D. The expansion cohort will randomize participants (1:1) in two groups to evaluate two alternate dose modification guidelines for corneal AEs. Part 2 will further evaluate the safety and assess the preliminary clinical activity of the belantamab mafodotin RP2D in combination with DPd. Overall, approximately 48 participants will be enrolled in the study. Participant follow-up will continue up to 3 years after the last participant is randomized. The estimated accrual period will be 12 months corresponding to an approximate total study duration of 4 years.

NCT ID: NCT05560217 Not yet recruiting - Clinical trials for Disease of the Blood

Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects

Start date: October 10, 2022
Phase:
Study type: Observational

In accordance with the selection criteria, component blood collection will be carried out and peripheral blood mononuclear cells will be isolated, cryopreserved and in vitro culture of peripheral blood mononuclear cells. Cultivating cells under normal culture conditions or potential drug molecule treatment, observing and recording key parameters such as cell viability, proliferation, apoptosis and functional gene expression, will also provide an important reference for the production of CAR-T cell drugs.

NCT ID: NCT05541835 Not yet recruiting - Clinical trials for Hematologic Diseases

Hematological Abnormalities in Children

Start date: March 20, 2023
Phase:
Study type: Observational

the aim of the study is to determine Hematological abnormalities in Congenital Cyanotic Heart Disease

NCT ID: NCT05495802 Not yet recruiting - Bone Metastases Clinical Trials

Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

OOSLOH
Start date: December 2022
Phase:
Study type: Observational

Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap. Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures. To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient

NCT ID: NCT05473650 Not yet recruiting - Pancytopenia Clinical Trials

Spectrum of Hematological Disorders in Pediatrics

Start date: September 1, 2022
Phase:
Study type: Observational

To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year

NCT ID: NCT05324917 Not yet recruiting - Children Clinical Trials

Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases

Start date: April 10, 2022
Phase:
Study type: Observational

To establish a population pharmacokinetic and pharmacodynamic model of rituximab in children with hemopathy. To optimize the administration of rituximab in the treatment of children based on pharmacokinetic model.

NCT ID: NCT05305534 Not yet recruiting - Blood Disease Clinical Trials

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

Start date: November 2023
Phase:
Study type: Observational

Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods